Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has provided an update.
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the cancer immunotherapy drug Nivolumab, in the Indian market, reinforcing its capabilities in advanced biologics and immuno-oncology. Offered in 100 mg and 40 mg dosages at roughly one-quarter the price of the reference drug, Tishtha is designed to significantly improve affordability and reduce the overall treatment burden for cancer patients, with the company estimating potential benefit for more than 500,000 patients. The two-strength portfolio aims to help oncologists optimise dosing and minimise drug wastage, while domestic development and manufacturing are intended to ensure consistent, long-term availability of checkpoint inhibitor therapy across multiple treatment cycles, enhancing access to modern cancer care in India and strengthening Zydus’s position in the oncology and biosimilars space.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint spanning the United States, India and other international markets. As of September 30, 2025, the group employed around 29,000 people worldwide, including 1,500 R&D scientists, and focuses on delivering quality healthcare solutions and path‑breaking discoveries to transform lives.
Average Trading Volume: 23,884
Technical Sentiment Signal: Hold
Current Market Cap: 886.6B INR
Find detailed analytics on ZYDUSLIFE stock on TipRanks’ Stock Analysis page.